Fierce Biotech1d
Daiichi taps Nosis to deliver RNA therapies beyond the liver
Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
MedPage Today on MSN2d
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC
Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
DelveInsight Business Research, LLP: TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fierce Biotech6d
Merck KGaA fails midphase lupus trial arm, says totality of data support further development
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...